Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Solid Tumors: early-phase trial registry
15 of 21 indexed Metastatic Solid Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 15 currently recruiting · #797 of 28,707 conditions by registered trial count
Metastatic Solid Tumors: 21 US clinical trials tracked, 15 recruiting.
Metastatic Solid Tumors is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is Turning Point Therapeutics, running 3 of these trials.
Enrollment posture brief
Registry condition metastatic-solid-tumors
OPEN 15 | RECR 71% | LATE 1 | EARLY 19 | RANK #797 | SPON 3
Volume-matched condition peers
Nearest open-share peer: ACL Tear (71% recruiting · 7 trials)
Metastatic Solid Tumors lists 15 open slots (71% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Solid Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Solid Tumors is recruiting above its size-band peers.
15 of 21 indexed trials (71.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Solid Tumors trials is spread across many organizations.
Turning Point Therapeutics accounts for 3 of 21 trials (14.3%). 16 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Solid Tumors enrolment sits around 178 participants.
Median target enrolment is 178 among the 21 trials that report a genuine target (sentinel values excluded). 9 of those (42.9%) plan for fewer than 100 participants.
-
Metastatic Solid Tumors research is mostly interventional.
21 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeiGene
NCT06585488
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Turning Point Therapeutics
NCT03093116
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Avenzo Therapeutics
NCT07038343
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
NCT05836324
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines
NCT07397338
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics
NCT07193511
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT06031441
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Daiichi Sankyo
NCT06660654
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Erasca
NCT06983743
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Erasca
NCT07021898
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Merck Sharp & Dohme
NCT05853367
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics
NCT04094610
SLV-324 Treatment of Metastatic Solid Tumors
Solve Therapeutics
NCT07108114
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
Trutino Biosciences
NCT06770764
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
New Phase
NCT07224464
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie
NCT03893955
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
Turning Point Therapeutics
NCT03993873
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Incyte Corporation
NCT06873789
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Gilead Sciences
NCT04319198
M1231 in Participants With Solid Tumors
EMD Serono Research & Development Institute
NCT04695847
Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT02281409
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Solid Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Solid Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Solid Tumors page
21 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Metastatic Solid Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Turning Point Therapeutics sponsors the most Metastatic Solid Tumors trials on record, review their full trial history before evaluating a specific study. See Turning Point Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Solid Tumors condition card totals 21 registered trials; most-linked intervention Oral repotrectinib (TPX-0005); top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.